Transcriptome and interactome analyses identify the TP53 interacting gene RCCD1 as a candidate susceptibility gene at the 15p26.1 breast and ovarian cancer risk locus
Authors:
- Jasmine T PlummerJPJasmine T Plummer
- Felipe Segato DezemFDFelipe Segato Dezem
- Stephanie S. ChenSCStephanie S. Chen
- Subash DhunganaSDSubash Dhungana
- Deepika WaliDWDeepika Wali
- Brian DavisBDBrian Davis
- Justyna KanskaJKJustyna Kanska
- Niko SafiNSNiko Safi
- Ji-Heui SeoJSJi-Heui Seo
- Rosario I CoronaRCRosario I Corona
- Joellen M SchildkrautJSJoellen M Schildkraut
- Paul Dp PharoahPPPaul Dp Pharoah
Preprint
Abstract
Common genetic variation in a region on chromosome 15q26 confers susceptibility to breast and ovarian cancer. The P53 interacting gene RCCD1 in this region is a candidate susceptibility gene for both cancers. In this study, a colocalization analysis of breast and ovarian cancer case-control genetic association studies in over 145,000 and 146,000 controls fine mapped the shared association in this region to 17 pleiotropic credible causal risk variants ( P breast < 1.16 × 10 −14 and P ovary < 7.50 × 10 −7 ). These variants were strongly associated with the expression of RCCD1 in normal breast and ovarian tissues. Circular chromosome conformation capture (4C) analysis of RCCD1 in breast and ovarian cancer cells identified similar patterns of cis -interaction and significant binding site enrichment for the BRCA2 interacting gene EMSY (P adjusted = 9.24 × 10 −6 ). The 4C analysis pinpointed a single 2kB RCCD1 cis-interaction that contained two of the 17 shared risk variants. RCCD1 trans -interacting regions mapped to previously identified genome wide significant (P < 5 × 10 −8 ) breast cancer risk loci (1p34.2 and 3p14.1) and to the pleiotropic breast-ovarian cancer risk locus at chromosome 9q34.2. Stable overexpression of RCCD1 in breast and ovarian cancer precursor cells identified 13 and 11 differentially expressed genes (DEGs) respectively associated with breast and ovarian cancer risk at genome-wide significance ( P MAGMA < 2.6 × 10 −6 after Bonferroni correction). Eighty-two DEGs shared between breast and ovarian cancer were strongly enriched in TP53 (P = 9.9 × 10 −4 ), Hippo (P = 2.51 × 10 −3 ) and TNF signaling (P = 4.7 × 10 −3 ) pathways.Keywords
This publication has 105 references indexed in Scilit:
- Pan-Cancer Study Detects Novel Genetic Risk Variants and Shared Genetic Basis in Two Large CohortsbioRxiv, 2019
- Shared heritability and functional enrichment across six solid cancersNature Communications, 2019
- Quantifying the Genetic Correlation between Multiple Cancer TypesCancer Epidemiology, Biomarkers & Prevention, 2017
- Ovarian cancer and hormone replacement therapy in the Million Women StudyThe Lancet, 2007
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer FamiliesThe American Journal of Human Genetics, 1998
- Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 geneNature Genetics, 1997
- BRCA2 mutations in primary breast and ovarian cancersNature Genetics, 1996
- Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlationNature Genetics, 1995
- BRCA1 Mutations in Primary Breast and Ovarian CarcinomasScience, 1994